Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs [Yahoo! Finance]
Jaguar Health, Inc. (JAGX)
US:NASDAQ Investor Relations:
jaguarhealth.gcs-web.com/investor-overview
Company Research
Source: Yahoo! Finance
room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs Canalevia ® -CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA Jaguar is attending the December 3-5 Pet Connect conference and is available for NP300 partnership discussions at the event SAN FRANCISCO, CA / ACCESSWIRE / November 22, 2024 / Jaguar Health, Inc. NASDAQ:JAGX ) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhea in dogs, in exchange for commercial rights to the product in the U.S. NP300 is a novel antisecretory drug with a similar mechanism of action to Canalevia ® -CA1 (crofelemer delayed-release tablets), the company's conditional
Show less
Read more
Impact Snapshot
Event Time:
JAGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAGX alerts
High impacting Jaguar Health, Inc. news events
Weekly update
A roundup of the hottest topics
JAGX
News
- Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in DogsAccesswire
- Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe” [Yahoo! Finance]Yahoo! Finance
- Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”Accesswire
- Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]Yahoo! Finance
JAGX
Sec Filings
- 11/13/24 - Form 424B5
- 11/13/24 - Form 8-K
- 11/13/24 - Form 10-Q
- JAGX's page on the SEC website